Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

PEXIDARTINIB vs VIMSELTINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

PEXIDARTINIB vs VIMSELTINIB: Safety Overview

Metric PEXIDARTINIB VIMSELTINIB
Total FAERS Reports 970 170
Deaths Reported 17 0
Death Rate 1.8% N/A
Hospitalizations 91 5
Average Patient Age 44.9 yrs 45.6 yrs
% Female Patients 63.4% 55.4%
FDA Approval Date Aug 2, 2019 Feb 14, 2025
Manufacturer Daiichi Sankyo Inc. Deciphera Pharmaceuticals, LLC
Route ORAL ORAL
Marketing Status Discontinued Prescription